Several pre-clinical studies have demonstrated that targeting TAMs via the CCL2-CCR2 pathway, with CCR2 antagonists or CCL2 neutralizing antibodies, increases the survival of tumor-bearing mice [129,130]. Here, CCR2 is linked to neoplasm.